{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:31:06Z","timestamp":1775251866115,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI068963-01"],"award-info":[{"award-number":["RO1 AI068963-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI088106-01"],"award-info":[{"award-number":["RO1 AI088106-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI144903"],"award-info":[{"award-number":["RO1 AI144903"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["RO1 DK107992-01"],"award-info":[{"award-number":["RO1 DK107992-01"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clim.2023.109807","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T06:57:14Z","timestamp":1696921034000},"page":"109807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Profiling of mouse and human liver diseases identifies targets for therapeutic treatment of autoimmune hepatitis"],"prefix":"10.1016","volume":"256","author":[{"given":"Monica","family":"Centa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Thermidor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Isabel","family":"Fiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantina","family":"Alexandropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.clim.2023.109807_bb0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/liv.13682","article-title":"Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening","volume":"38","author":"Marcellin","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.clim.2023.109807_bb0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12916-014-0159-5","article-title":"The global burden of liver disease: a challenge for methods and for public health","volume":"12","author":"Byass","year":"2014","journal-title":"BMC Med."},{"issue":"23","key":"10.1016\/j.clim.2023.109807_bb0015","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.3748\/wjg.v27.i23.3249","article-title":"Update on the management and treatment of viral hepatitis","volume":"27","author":"Almeida","year":"2021","journal-title":"World J. Gastroenterol."},{"issue":"16","key":"10.1016\/j.clim.2023.109807_bb0020","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3748\/wjg.v27.i16.1691","article-title":"From hepatitis A to E: A critical review of viral hepatitis","volume":"27","author":"Castaneda","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.clim.2023.109807_bb0025","doi-asserted-by":"crossref","first-page":"18017","DOI":"10.1038\/nrdp.2018.17","article-title":"Autoimmune hepatitis","volume":"4","author":"Mieli-Vergani","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.clim.2023.109807_bb0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaut.2015.10.006","article-title":"The clinical phenotypes of autoimmune hepatitis: a comprehensive review","volume":"66","author":"Wang","year":"2016","journal-title":"J. Autoimmun."},{"issue":"6","key":"10.1016\/j.clim.2023.109807_bb0035","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.clim.2023.109807_bb0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.clim.2023.109807_bb0045","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/gutjnl-2017-315691","article-title":"Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation","volume":"67","author":"Ibrahim","year":"2018","journal-title":"Gut."},{"key":"10.1016\/j.clim.2023.109807_bb0050","series-title":"Innovative Medicine: Basic Research and Development. Tokyo","first-page":"149","author":"Ogawa","year":"2015"},{"issue":"7","key":"10.1016\/j.clim.2023.109807_bb0055","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.clim.2023.109807_bb0060","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/gut.52.11.1638","article-title":"Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C","volume":"52","author":"Asselah","year":"2003","journal-title":"Gut."},{"issue":"4","key":"10.1016\/j.clim.2023.109807_bb0065","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00281-021-00881-w","article-title":"Functional heterogeneity of CD4(+) T cells in liver inflammation","volume":"43","author":"Muscate","year":"2021","journal-title":"Semin. Immunopathol."},{"issue":"2","key":"10.1016\/j.clim.2023.109807_bb0070","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jhep.2021.03.016","article-title":"Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4(+) T cells in primary sclerosing cholangitis","volume":"75","author":"Poch","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.clim.2023.109807_bb0075","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/231210","article-title":"Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C","volume":"2012","author":"Neuman","year":"2012","journal-title":"Int. J. Hepatol."},{"issue":"9865","key":"10.1016\/j.clim.2023.109807_bb0080","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.clim.2023.109807_bb0085","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2023.109807_bb0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2013.06.013","article-title":"Mucosal immunity in liver autoimmunity: a comprehensive review","volume":"46","author":"Trivedi","year":"2013","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.clim.2023.109807_bb0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell."},{"issue":"1","key":"10.1016\/j.clim.2023.109807_bb0100","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3390\/ijms16011980","article-title":"Medullary thymic epithelial cells and central tolerance in autoimmune hepatitis development: novel perspective from a new mouse model","volume":"16","author":"Alexandropoulos","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.clim.2023.109807_bb0105","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1172\/JCI65414","article-title":"Medullary thymic epithelial cell depletion leads to autoimmune hepatitis","volume":"123","author":"Bonito","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2023.109807_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102808","article-title":"Impaired central tolerance induces changes in the gut microbiota that exacerbate autoimmune hepatitis","volume":"128","author":"Centa","year":"2022","journal-title":"J. Autoimmun."},{"issue":"12","key":"10.1016\/j.clim.2023.109807_bb0115","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"issue":"1","key":"10.1016\/j.clim.2023.109807_bb0120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun. Signal"},{"issue":"9","key":"10.1016\/j.clim.2023.109807_bb0125","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"18","key":"10.1016\/j.clim.2023.109807_bb0130","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: a review in rheumatoid arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs."},{"issue":"7","key":"10.1016\/j.clim.2023.109807_bb0135","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/bioinformatics\/btx752","article-title":"Reactome diagram viewer: data structures and strategies to boost performance","volume":"34","author":"Fabregat","year":"2018","journal-title":"Bioinformatics."},{"issue":"3","key":"10.1016\/j.clim.2023.109807_bb0140","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","article-title":"Classification of chronic viral hepatitis: a need for reassessment","volume":"13","author":"Scheuer","year":"1991","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.clim.2023.109807_bb0145","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/lt.21949","article-title":"Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant","volume":"15","author":"Ward","year":"2009","journal-title":"Liver Transpl."},{"issue":"9","key":"10.1016\/j.clim.2023.109807_bb0150","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41584-018-0058-9","article-title":"S100 proteins in rheumatic diseases","volume":"14","author":"Austermann","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"issue":"2","key":"10.1016\/j.clim.2023.109807_bb0155","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/pr.119.018440","article-title":"Targeting Janus kinases and signal transducer and activator of transcription 3 to treat inflammation, fibrosis, and cancer: rationale, progress, and caution","volume":"72","author":"Bharadwaj","year":"2020","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.clim.2023.109807_bb0160","first-page":"4883","article-title":"The JAK inhibitor tofacitinib ameliorates immune-mediated liver injury in mice","volume":"20","author":"Wang","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.clim.2023.109807_bb0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaut.2018.10.020","article-title":"Etiopathogenesis of autoimmune hepatitis","volume":"95","author":"Floreani","year":"2018","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.clim.2023.109807_bb0170","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jcmgh.2021.09.004","article-title":"Tofacitinib-induced modulation of intestinal adaptive and innate immunity and factors driving cellular and systemic pharmacokinetics","volume":"13","author":"Zollner","year":"2022","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.clim.2023.109807_bb0175","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2023.109807_bb0180","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jdermsci.2020.12.007","article-title":"Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma","volume":"101","author":"Aung","year":"2021","journal-title":"J. Dermatol. Sci."},{"issue":"4","key":"10.1016\/j.clim.2023.109807_bb0185","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/rheumatology\/keaa670","article-title":"Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sjogren\u2019s syndrome","volume":"60","author":"Barrera","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.clim.2023.109807_bb0190","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40246-020-00301-4","article-title":"Genetic risk factors for autoimmune hepatitis: implications for phenotypic heterogeneity and biomarkers for drug response","volume":"15","author":"Higuchi","year":"2021","journal-title":"Hum. Genom."},{"issue":"4","key":"10.1016\/j.clim.2023.109807_bb0195","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.dld.2006.03.001","article-title":"Primary biliary cirrhosis: when and why does the disease develop?","volume":"38","author":"Floreani","year":"2006","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.clim.2023.109807_bb0200","article-title":"Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: a multicenter, retrospective study, Clin","author":"Schregel","year":"2023","journal-title":"Gastroenterol. Hepatol"},{"issue":"3","key":"10.1016\/j.clim.2023.109807_bb0205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"468","key":"10.1016\/j.clim.2023.109807_bb0210","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat0344","article-title":"Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis","volume":"10","author":"Zhu","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.clim.2023.109807_bb0215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1369\/0022155415627681","article-title":"TGF-beta\/SMAD pathway and its regulation in hepatic fibrosis","volume":"64","author":"Xu","year":"2016","journal-title":"J. Histochem. Cytochem."},{"issue":"4","key":"10.1016\/j.clim.2023.109807_bb0220","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/JLB.2RI0717-278R","article-title":"Biology of IL-2 and its therapeutic modulation: mechanisms and strategies","volume":"103","author":"Mitra","year":"2018","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.clim.2023.109807_bb0225","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity."},{"issue":"1","key":"10.1016\/j.clim.2023.109807_bb0230","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.clim.2023.109807_bb0235","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/art.41906","article-title":"A decade of JAK inhibitors: what have we learned and what may be the future?","volume":"73","author":"Liu","year":"2021","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.clim.2023.109807_bb0240","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11899-020-00596-z","article-title":"The next generation of JAK inhibitors: an update on fedratinib, momelotonib, and pacritinib","volume":"15","author":"Patel","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"1","key":"10.1016\/j.clim.2023.109807_bb0245","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"issue":"4","key":"10.1016\/j.clim.2023.109807_bb0250","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1084\/jem.20040131","article-title":"CD24 controls expansion and persistence of autoreactive T cells in the central nervous system during experimental autoimmune encephalomyelitis","volume":"200","author":"Bai","year":"2004","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.clim.2023.109807_bb0255","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12016-015-8470-2","article-title":"CD24: from a hematopoietic differentiation antigen to a genetic risk factor for multiple autoimmune diseases","volume":"50","author":"Tan","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.clim.2023.109807_bb0260","doi-asserted-by":"crossref","first-page":"23533","DOI":"10.1038\/srep23533","article-title":"An essential role for the transcription factor Runx1 in T cell maturation","volume":"6","author":"Hsu","year":"2016","journal-title":"Sci. Rep."},{"issue":"36","key":"10.1016\/j.clim.2023.109807_bb0265","doi-asserted-by":"crossref","first-page":"14592","DOI":"10.1073\/pnas.1200037109","article-title":"Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFbeta interaction","volume":"109","author":"Cunningham","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6223","key":"10.1016\/j.clim.2023.109807_bb0270","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.aaa0314","article-title":"Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFbeta-SMMHC delays leukemia in mice","volume":"347","author":"Illendula","year":"2015","journal-title":"Science."},{"issue":"8","key":"10.1016\/j.clim.2023.109807_bb0275","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/s41375-019-0403-2","article-title":"RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation","volume":"33","author":"Zhou","year":"2019","journal-title":"Leukemia."},{"key":"10.1016\/j.clim.2023.109807_bb0280","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3389\/fphys.2017.00508","article-title":"Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to Nano therapeutics","volume":"8","author":"Gao","year":"2017","journal-title":"Front. Physiol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623005703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623005703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:10:30Z","timestamp":1761495030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661623005703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":56,"alternative-id":["S1521661623005703"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2023.109807","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profiling of mouse and human liver diseases identifies targets for therapeutic treatment of autoimmune hepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2023.109807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109807"}}